- Home
- Automated
- List of product information
- TEVETEN TABLET 600 MG [SIN11807P]
TEVETEN TABLET 600 MG [SIN11807P]
Active ingredients: TEVETEN TABLET 600 MG
Last updated 26 October 2025
Product Info
TEVETEN TABLET 600 MG
[SIN11807P]
Product information
Active Ingredient and Strength | EPROSARTAN (AS EPROSARTAN MESYLATE) - 600 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | SOLVAY PHARMACEUTICALS B V - NETHERLANDS |
Registration Number | SIN11807P |
Licence Holder | ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | C09CA02 |
Indication
Treatment of essential hypertension.
Posology and method of administration
The recommended dose is 600 mg once daily, to be taken in the morning.
The dose may be increased to a maximum of 800 mg daily, depending on the blood pressure response, until satisfactory response is achieved. Achievement of maximal blood pressure reduction in most patients may take 2 to 3 weeks of treatment.
Doses up to 1200 mg per day, for 8 weeks, have been shown in clinical trials to be effective with no apparent dose relationship in the incidence of adverse experiences reported.
Teveten™ may be used alone or in combination with other antihypertensives, e.g. thiazide-type diuretics or calcium channel blockers, if a greater blood pressure lowering effect is required.
Teveten™ may be taken with or without food.
Elderly (> 75 years): As clinical experience is limited in patients over 75 years, a starting dose of 300 mg once daily is recommended.
Dosage in hepatically impaired patients: There is limited experience in patients with hepatic impairment (see section Contra-indications and section Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). In patients with mild to moderate hepatic impairment, a starting dose of 300 mg once daily is recommended.
Dosage in renally impaired patients: No dose adjustment is required in patients with creatinine clearance 60–80 ml/min. As clinical experience is limited in patients with creatinine clearance <60ml/min, a starting dose of 300mg once daily is recommended (see Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Contra-indications
Known hypersensitivity to components of the product. Pregnancy and lactation. Severe hepatic impairment.
The concomitant use of Teveten™ with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73m2) (see Interactions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).